Inventiva S.A.
IVA
Rank in Stocks
#9176
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Share Price
$4.31
Last synced: 2026-11-09
Market Cap
$893.57M
Change (1 day)
1.73%
Change (1 year)
-3.88%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Inventiva S.A. (IVA)
Category
Healthcare
Operating Margin for Inventiva S.A. (IVA)
Operating Margin as of November 2026 TTM: -306,726.53%
According to Inventiva S.A.'s latest financial reports, its current operating margin (TTM) is -306,726.53%. At the end of 2025 the company had an operating margin of -3,040.98%.
Operating Margin history for Inventiva S.A. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -306,726.53% | 9,986.44% |
| 2025 | -3,040.98% | 358.96% |
| 2024 | -662.58% | 12.75% |
| 2023 | -587.68% | 25.33% |
| 2022 | -468.92% | -62.26% |
| 2021 | -1,242.58% | -84.45% |
| 2020 | -7,988.71% | 1,744.33% |
| 2019 | -433.15% | -58.36% |
| 2018 | -1,040.13% | 224.27% |
| 2017 | -320.76% | 132.72% |
| 2016 | -137.83% | -56.68% |
| 2015 | -318.17% | -22.44% |
| 2014 | -410.22% | 0.84% |
| 2013 | -406.81% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Inventiva S.A.'s operating margin
What is Inventiva S.A.'s operating margin?
Inventiva S.A.'s operating margin is -306,726.53%, as of Nov 2026.
What was Inventiva S.A.'s operating margin in 2025?
In 2025, Inventiva S.A.'s operating margin was -3,040.98%, compared with -662.58% in 2024.
How has Inventiva S.A.'s operating margin changed since 2020?
From 2020 to 2025, Inventiva S.A.'s operating margin was highest in 2022 (-468.92%) and lowest in 2020 (-7,988.71%).
How does Inventiva S.A.'s operating margin compare with similar companies?
Inventiva S.A.'s operating margin (-306,726.53%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.